| P2093 | author name string | Kevin A. Schulman | |
| | Sean R. Tunis | |
| P2860 | cites work | Why Medicare has not established criteria for coverage decisions | Q80107438 |
| | Coverage options for promising technologies: Medicare's 'coverage with evidence development' | Q80244066 |
| | Oncogenic pathway signatures in human cancers as a guide to targeted therapies | Q29615526 |
| | Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer | Q33996115 |
| | Pharmacogenomics--drug disposition, drug targets, and side effects | Q34175616 |
| | Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose | Q34423204 |
| | A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. | Q34555834 |
| | Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer | Q34767549 |
| | Economic implications of potential changes to regulatory and reimbursement policies for medical devices | Q36293520 |
| | Fueling innovation in medical devices (and beyond): venture capital in health care | Q44263403 |
| | The prognostic role of a gene signature from tumorigenic breast-cancer cells. | Q55042952 |
| | Parity, Oral Contraceptives, and the Risk of Ovarian Cancer among Carriers and Noncarriers of aBRCA1orBRCA2Mutation | Q57250729 |
| | Ethical and scientific implications of the globalization of clinical research | Q58670198 |
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1157-1159 | |
| P577 | publication date | 2010-11-01 | |
| P1433 | published in | Nature Biotechnology | Q1893837 |
| P1476 | title | A policy approach to the development of molecular diagnostic tests | |
| P478 | volume | 28 | |